{"name":"Kura Oncology, Inc.","slug":"kura-oncology-inc","ticker":"","exchange":"","domain":"kuraoncology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cytarabine (Ara-C)","genericName":"Cytarabine (Ara-C)","slug":"cytarabine-ara-c","indication":"Acute myeloid leukemia (AML)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Darlifarnib","genericName":"Darlifarnib","slug":"darlifarnib","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Cytarabine (Ara-C)","genericName":"Cytarabine (Ara-C)","slug":"cytarabine-ara-c","phase":"phase_3","mechanism":"Cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to chain termination and cell death, particularly affecting rapidly dividing cells.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML)","Lymphoma"],"catalyst":""},{"name":"Darlifarnib","genericName":"Darlifarnib","slug":"darlifarnib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdHFCOEd6WUVsdVA0b0NDdEpRTXQzQVpDeV9UbUt2ZmdTM3BBZHNoSkE1RnNYMmVJeWpoUE1LNDZLZW96a0FlRVJ5Z0tUN1o2SFg5UVdIUWFKaEk2WERTRnVSVWxPM0dkSU9QaGQ1em92d24yVWt0MHhVNEN1RzZ5d1dLd1U5eE1uUnlad3hxY1ZJYWM5OHNmdERDRk90b0QwNnZpOXdn?oc=5","date":"2025-12-04","type":"regulatory","source":"San Diego Business Journal","summary":"Kura Oncology Secures FDA Approval of Leukemia Drug - San Diego Business Journal","headline":"Kura Oncology Secures FDA Approval of Leukemia Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOd0xJM3BPeGh4RThSMG9QTjdFMGswLXJSalQ5V0Z1MzhnY3ZydXgyTEFzZ2cyRlg3UHNqZFhiZ2xyR0kxZkFUam8wcHBrUzZVOE5ZcFM5WUktWTFNX2VIbnhOQURVSTNiam14ZjJpWVlhSU03RE9tWHRGcEVyZzNHTUdSZlNsazExdmEybzBNSUtnRzF1NmhFaWhDWHVpZ0pmQkszUQ?oc=5","date":"2025-11-14","type":"regulatory","source":"Pharmaceutical Technology","summary":"Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy - Pharmaceutical Technology","headline":"Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5","date":"2025-11-13","type":"regulatory","source":"Reuters","summary":"US FDA approves Kura-Kyowa's blood cancer therapy - Reuters","headline":"US FDA approves Kura-Kyowa's blood cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQaFZkVWRyaDE5cDhzbFVQT0NmbjBiZWo1WkpjeEZMUzhKaWMyMlpDRGRJZXB2SW95YzdWeXlfbjNrTnFvd25wcEx3RVRrdzFMbkF0cnNGUkdIZjFqRTdvZEVYSW1ZYV9MVUlLVVBtSmM3VHp0M0U1Q3RkUHI4WXBNRmpzcjJtb0pYUzBaNVMtVE5RMXB0T0NwbXEySWwwdw?oc=5","date":"2025-11-13","type":"regulatory","source":"MedCity News","summary":"FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma - MedCity News","headline":"FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBjZDJOclFRZFc3YXlSUHhqNWJuQWJ4NGNJMVowbHR4My10bnktUGg0a2JpbUxjREdhZmxBV1JReDd3cGV2QWRCNWo2Mkc5YzVZZll6WVpJVk1LZm1VUWVwaV9Ubm1sNWRRbWlnbTc4ak5uSktRNGNVNmVsQWd0RzQ?oc=5","date":"2025-11-13","type":"regulatory","source":"BioSpace","summary":"FDA Action Alert: BMS, Bayer, Arrowhead and More - BioSpace","headline":"FDA Action Alert: BMS, Bayer, Arrowhead and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNWjRqdTdlWmhYUHBnWXg2VjhZQVV1aTdBdm9FaVlqUEVyR05BSHFpcXJkQTZNMHF2T1RRcHd6cGRoa2JwemoxWWJFRHlMczR2aWJDRmZ6cE1YVktFRFJISzI2YXluWGtRS3hreU1NbnEwSzJoYjBBRERyMTlwdGpPTTZDajdiUnBtbEp3TkdYY291aWhQbU56cS1EM3FJT01Xb3FOZE42dUo3aHlwb1p4YjVTcXg3UVZCYzlfU1ZUWWpFQQ?oc=5","date":"2025-11-13","type":"regulatory","source":"Fierce Pharma","summary":"Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval - Fierce Pharma","headline":"Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQTklQVXRfOEdnTVh0Sm1iRHBobWNkUmQ5NkVCLVJ4dGN4eGwzaW05RjB2Mm9zdl8zd056VXhSdC1td1dteGx0dnAzdEh1TVFEYjItVmltNFU4VXJwY0pvT3NOVmNLT3Jndkt6Tk90UFdNd0NiVXJzMFd4ODYxemNRNWVVeVpEM1Jsd3lSNXFEZ1hPUQ?oc=5","date":"2025-10-31","type":"regulatory","source":"RTTNews","summary":"Biotech Stocks Facing FDA Decision In November 2025 - RTTNews","headline":"Biotech Stocks Facing FDA Decision In November 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNQ3FXb0hxWWNxeEhKXzFDZlNKQjhJcllCVEhjd2I0UVpJM0Q2c0M2WGduWU9ZdFNCM3JjRHI2OG0xc3RsTHlWc1hVUElYMi1Gcl9mYmd5M0FucGpyYTFmNzdxaEVXNEQwcmE3eWE5TWJncTZOMXNuYzJVZEhsTUlmQ2lkc3R3N05NU1Z1Rnc0V2xfTzV4VHJF?oc=5","date":"2025-10-31","type":"regulatory","source":"BioCentury","summary":"At least four PDUFA dates on FDA’s November docket - BioCentury","headline":"At least four PDUFA dates on FDA’s November docket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQX0FYc090Q2FxYUQwNG16QklWSGswNVJOQU9IdHlIVC1GUHBmOElQcDVRcEFtb1NNTU1SOGdOaV8yd2otMDVLRFREb1JYYkNvNURCemptWWppMFlISjZHWURJUHJLOTFVdjF0cWgtRVktWUlFaERaZmFvVG1YUHRYTXdBaFowa2FMaEpvOF9OQ0JFSm16b2VGaWhpS2tIMlg1aDE0QWJ5Y2FuMjA1?oc=5","date":"2025-09-19","type":"deal","source":"Seeking Alpha","summary":"Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy (NASDAQ:KURA) - Seeking Alpha","headline":"Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy (NASDAQ:KURA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFBfZ2x1YU12ZnRlR09Hd2szcjc4R1BZTWVPQXA1NmFqd1RUT3AwRkQwaVUzaXhzYlItZWk3T0ZLTGxtT29HQldDVm80OU9VWUx0MnVUZTdhOVFtZi1DSmtsM0pn?oc=5","date":"2025-09-02","type":"pipeline","source":"Fierce Pharma","summary":"Kura Oncology - Fierce Pharma","headline":"Kura Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPV1lFZFBJRTc2UGhsallqajFaVTBycEhab1JxTWdkc1VmOGMycWJLdkstbXNTM0c0YWpxX0E1ajdxZDZCNEwtOXBpVVV5VVNqa2JybThTbTVSNmJ3blh5RkdPR0lOR2tyUXBTYVZaa1htQUhEbTNhbWFtcVBtNklVRldHYm9Odm5HaU5fNHhSS2JPbGc1ZEZIS3d1REpXNkNzRkd0TnBDak1LYUtTaWVWMVI1UUVZQ3BQazVFM1B1RGJsby10YUpfdlVxa1ZMc3hZVjNvUmg0NHgxLUZyeTJwODRyQ1hFeDJ4VllsWFhTOTBrOEhMZUtSVXBYamxRMkN0b3pqN05tNmFkbmQzeDNDNE9mTWtDaWN3Y0tnMnNnY1Q0SlM2aTBFY0ZVU1lwSFQ1SVQ2cE5ORXp1bnBwY0V2cw?oc=5","date":"2025-07-15","type":"regulatory","source":"PR Newswire","summary":"Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire","headline":"Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBEbm5mWDRSUDBYYXNmTC1Sb1FkQXB4dHF4ZnBzV1daZDhJLTN2VVM1blU1U3JGV3k1Wll1U2xEQjYyWG1sVEdRRkZiVTlORmFUOTFmQjVoRm1oMEVuejMzb3U0MTRNcDVSQzJNTF9qSHE3bWtDbjlvSVZOQVU?oc=5","date":"2025-07-07","type":"pipeline","source":"Cancer Therapy Advisor","summary":"Opinion: Top Studies From EHA 2025 - Cancer Therapy Advisor","headline":"Opinion: Top Studies From EHA 2025","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}